Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

The number of adults diagnosed with diabetes has more than quadrupled since 1990 and now stands above 800 million, according ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

With new weight-loss drugs hailed as ‘miracle’ medicines, Harriet Symonds explores whether their increasing popularity should ...

2. Eli Lilly Eli Lilly is a hot growth stock to buy, as investors are bullish on its prospects in the weight loss market. The company has an incredibly promising product in tirzepatide, which ...

After a nurse died after just two weight-loss injections of Mounjaro - which is approved for use on the NHS - here's ...

Jim Gaffigan reveals his weight loss journey with Mounjaro tackling food addiction and societal stigma while balancing comedy ...

The drug tirzepatide, the medicine found in weight loss drugs Zepbound and Mounjaro, reduced the severity of sleep apnea. The ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...